Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis

被引：0

作者：

Hiligsmann, Mickael ^{[1
]}

Vanoverberghe, Marie ^{[1
]}

Neuprez, Audrey ^{[1
]}

Bruyere, Olivier ^{[1
]}

Reginster, Jean-Yves ^{[1
]}

机构：

[1] Univ Liege, HEC Sch Management, Pharmacoecon Unit Res, B-4000 Liege, Belgium

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2010年 / 10卷 / 04期

关键词：

cost-effectiveness; osteoporosis; strontium ranelate; treatment; POSTMENOPAUSAL WOMEN; ECONOMIC EVALUATIONS; VERTEBRAL FRACTURE; DRESS SYNDROME; BONE LOSS; RISK; BISPHOSPHONATES; HIP; MICROSIMULATION; EFFICACY;

D O I：

10.1586/ERP.10.53

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Strontium ranelate has been introduced recently for the prevention and treatment of osteoporosis in Europe and in many countries worldwide. This article reviews the published cost-effectiveness literature pertaining to strontium ranelate. Six studies were identified: two in the UK, two in Belgium and two in Sweden. The findings were consistent across the literature, suggesting that strontium ranelate is a cost-saving drug for women with osteoporosis aged over 80 years, and it is a cost-effective treatment compared with no treatment for osteoporotic women aged over 70 years and for younger women with clinical risk factors for fragility fracture. Strontium ranelate was also shown to be cost effective compared with branded risedronate in osteoporotic women aged over 75 years. Further analyses are required to assess the effectiveness and adherence to strontium ranelate in real-life settings, as well as to evaluate the cost-effectiveness of strontium ranelate in other countries and in populations of men.

引用

页码：359 / 366

页数：8

共 45 条

[1] Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers? [J].

Adachi, J. D. ;

Kennedy, C. C. ;

Papaioannou, A. ;

Ioannidis, G. ;

Leslie, W. D. ;

Walker, V. .

OSTEOPOROSIS INTERNATIONAL, 2009, 20 (10) :1785-1793

[2] Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? [J].

Bombardier, C ;

Maetzel, A .

ANNALS OF THE RHEUMATIC DISEASES, 1999, 58 :82-85

[3] An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting -: Based on the results of the SOTI and TROPOS trials [J].

Borgstrom, F. ;

Jonsson, B. ;

Strom, O. ;

Kanis, J. A. .

OSTEOPOROSIS INTERNATIONAL, 2006, 17 (12) :1781-1793

[4] The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis [J].

Borgstrom, F. ;

Strom, O. ;

Coelho, J. ;

Johansson, H. ;

Oden, A. ;

McCloskey, E. ;

Kanis, J. A. .

OSTEOPOROSIS INTERNATIONAL, 2010, 21 (02) :339-349

[5] Health economics of osteoporosis [J].

Borgstrom, Fredrik ;

Kanis, John A. .

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (05) :885-900

[6]

Breart G, 2010, OSTEOPOROSIS INT, V21, P166

[7]

Briggs A., 2006, Modelling methods for health economic evaluation

[8] Summary of meta-analyses of therapies for postmenopausal osteoporosis [J].

Cranney, A ;

Guyatt, G ;

Griffith, L ;

Wells, G ;

Tugwell, P ;

Rosen, C .

ENDOCRINE REVIEWS, 2002, 23 (04) :570-578

[9] Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report [J].

Drummond, Michael ;

Barbieri, Marco ;

Cook, John ;

Glick, Henry A. ;

Lis, Joanna ;

Malik, Farzana ;

Reed, Shelby D. ;

Rutten, Frans ;

Sculpher, Mark ;

Severens, Johan .

VALUE IN HEALTH, 2009, 12 (04) :409-418

[10] The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis - A structured review of the literature [J].

Fleurence, Rachael L. ;

Iglesias, Cynthia P. ;

Johnson, Jeanene M. .

PHARMACOECONOMICS, 2007, 25 (11) :913-933

← 1 2 3 4 5 →